Noninvasive diagnosis of chemotherapy related cardiotoxicity

Current Cardiology Reviews

Volumn 7, Issue 4, 2011, Pages 234-244

  Gillespie, Hamilton S ^a   Mcgann, Christopher J ^a   Wilson, Brent D ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Chemotherapy related cardiotoxicity; Noninvasive imaging; Nonischemic cardiomyopathy

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; LIPOSOME; MITOXANTRONE; RAZOXANE; SERUM ALBUMIN; TECHNETIUM 99M; THALLIUM; TRASTUZUMAB; TROPONIN; VINCRISTINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIOCARDIOGRAPHY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; DRUG DELIVERY SYSTEM; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; HEART ATRIUM FIBRILLATION; HEART INJURY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HEART MUSCLE ISCHEMIA; HUMAN; LIPOSOMAL DELIVERY; MEDICAL ASSESSMENT; NON INVASIVE PROCEDURE; NUCLEAR MEDICINE; PATIENT MONITORING; PATIENT SAFETY; PERICARDIAL EFFUSION; PRIORITY JOURNAL; RADIOISOTOPE VENTRICULOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THROMBOGENESIS;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARDIAC IMAGING TECHNIQUES; CARDIOMYOPATHIES; HUMANS; NEOPLASMS; TROPONIN; VENTRICULAR FUNCTION, LEFT;

EID: 84861307786     PISSN: 1573403X     EISSN: 18756557     Source Type: Journal    
DOI: 10.2174/157340311799960672     Document Type: Review

References (45)

1. Cardinale D, Colombo A, Sandri MT, et al. Prevention of highdose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114(23): 2474-81.
2. Bosch X, Esteve J, Sitges M, et al. Prevention of chemotherapyinduced left ventricular dysfunction with enalapril and carvedilol: rationale and design of the OVERCOME trial. J Card Fail 2011; 17(8): 643-8.
3. Seidman A, Hudis C, Pierri MK, et al. Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience. Journal of Clinical Oncology 2002; 20(5): 1215-21.
4. Shapira J, Gotfried M, Lishner M, et al. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation. Cancer 1990; 65(4): 870-3.
5. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982;96(2):133-9.
6. Von Hoff DD, Layard MW, Basa P, Davis HL, Jr., Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979 Nov; 91(5): 710-7.
7. Alter P, Herzum M, Soufi M, et al. Cardiotoxicity of 5-fluorouracil. Cardiovasc Hematol Agents Med Chem 2006; 4(1): 1-5.
8. Braverman A, Antin J, Plappert M, et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clinical Oncol 1991; 9(7): 1215-23.
9. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-Type Natriuretic Peptide in the Evaluation and Management of Acute Dyspnea. New Eng J Med 2004; 350(7): 647-54.
10. Cardinale D, Sandri MT. Role of Biomarkers in Chemotherapy-Induced Cardiotoxicity. Prog Cardiovasc Dis 2010; 53(2):121-9.
11. Cardinale D, Sandri MT, Colombo A, et al. Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy. Circulation 2004; 109(22): 2749-54.
12. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000; 36(2): 517-22.
13. Herman EH, Zhang J, Lipshultz SE, Rifai N, et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999; 17(7): 2237-43.
14. Lipshultz SE, Rifai N, Sallan SE, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997; 96(8): 2641-8.
15. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000; 22(4): 263-302.
16. Jensen Sr A, Hasbak P, Mortensen J, et al. Fluorouracil Induces Myocardial Ischemia With Increases of Plasma Brain Natriuretic Peptide and Lactic Acid but Without Dysfunction of Left Ventricle. J Clin Oncol 2010; 28(36): 5280-6.
17. Nousiainen T, Jantunen E, Vanninen E, et al. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer 2002; 86(11): 1697-700.
18. Nousiainen T, Vanninen E, Jantunen E, et al. Comparison of echocardiography and radionuclide ventriculography in the follow-up of left ventricular systolic function in adult lymphoma patients during doxorubicin therapy. J Internal Med 2001; 249(4): 297-303.
19. Mettler FA, Huda W, Yoshizumi TT, et al. Effective Doses in Radiology and Diagnostic Nuclear Medicine: A Catalog1. Radiology 2008; 248(1): 254-63.
20. Shankar SM, Marina N, Hudson MM, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics 2008; 121(2): e387-96.
21. Scott-Moncrieff A, Yang J, Levine D, et al. Real-world estimated effective radiation doses from commonly used cardiac testing and procedural modalities. Can J Cardiol 2011; 27(5): 613-8.
22. Radiation CtAHRfEtLLoI. Health Risks from Exposure to Low Levels of Ionizing Radiation (BEIR VII Phase 2). National Academies Press. 2006.
23. Yu CM, Sanderson JE, Marwick TH, et al. Tissue Doppler imaging a new prognosticator for cardiovascular diseases. J Am Coll Cardiol 2007; 49(19): 1903-14.
24. Jassal DS, Han S-Y, Hans C, et al. Utility of Tissue Doppler and Strain Rate Imaging in the Early Detection of Trastuzumab and Anthracycline Mediated Cardiomyopathy. J Am Society Echocardiograp 2009; 22(4): 418-24.
25. Fallah-Rad N, Walker JR, Wassef A, et al. The Utility of Cardiac Biomarkers, Tissue Velocity and Strain Imaging, and Cardiac Magnetic Resonance Imaging in Predicting Early Left Ventricular Dysfunction in Patients With Human Epidermal Growth Factor Receptor II-Positive Breast Cancer Treated With Adjuvant Trastuzumab Therapy. J Am Coll Cardiol; 57(22): 2263-70.
26. Nagy A, Cserép Z, Tolnay E, et al. Early Diagnosis of Chemotherapy-induced Cardiomyopathy: a Prospective Tissue Doppler Imaging Study. Pathol & Oncol Res 2008; 14(1): 69-77.
27. Caiani EG, Corsi C, Zamorano J, et al. Improved semiautomated quantification of left ventricular volumes and ejection fraction using 3-dimensional echocardiography with a full matrix-array transducer: comparison with magnetic resonance imaging. J Am Soc Echocardiogr 2005; 18(8): 779-88.
28. Miller JM, Rochitte CE, Dewey M, et al. Diagnostic performance of coronary angiography by 64-row CT. N Engl J Med 2008; 359(22): 2324-36.
29. Taylor AJ, Cerqueira M, Hodgson JM, et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 Appropriate Use Criteria for Cardiac Computed Tomography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance. Circulation. Nov 23;122(21):e525-55.
30. van der Geest RJ, Reiber JHC. Quantification in cardiac MRI. Journal of Magnetic Resonance Imaging. 1999;10(5):602-8.
31. Walker J, Bhullar N, Fallah-Rad N, Lytwyn M, Golian M, Fang T, et al. Role of Three-Dimensional Echocardiography in Breast Cancer: Comparison With Two-Dimensional Echocardiography, Multiple-Gated Acquisition Scans, and Cardiac Magnetic Resonance Imaging. Journal of Clinical Oncology. July 20, 2010;28(21):3429-36.
32. Skouri HN, Dec GW, Friedrich MG, Cooper LT. Noninvasive Imaging in Myocarditis. J Am Coll Cardiol. 2006 November 21, 2006;48(10):2085-93.
33. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et al. Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper. J Am Coll Cardiol. 2009 April 28, 2009;53(17):1475-87.
34. Fallah-Rad N, Lytwyn M, Fang T, Kirkpatrick I, Jassal DS. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson. 2008;10:5.
35. Wu CF, Chuang WP, Li AH, Hsiao CH. Cardiac magnetic resonance imaging in sunitinib malate-related cardiomyopathy: no late gadolinium enhancement. J Chin Med Assoc. 2009 Jun;72(6):323-7.
36. Jessup M, Abraham WT, Casey DE, Feldman AM, et al. 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation. Circulation. 2009 April 14, 2009;119(14):1977-2016.
37. Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol. 2009 Apr;10(4):391-9.
38. van Dalen EC, van den Brug M, Caron HN, Kremer LC. Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. Eur J Cancer. 2006 Dec;42(18):3199-205.
39. Shankar SM, Marina N, Hudson MM, Hodgson DC, Adams MJ, Landier W, et al. Monitoring for Cardiovascular Disease in Survivors of Childhood Cancer: Report From the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics. 2008 February 2008;121(2):e387-e96.
40. Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM, Schwartz RG, Shaffer EM, et al. Guidelines for Cardiac Monitoring of Children During and After Anthracycline Therapy: Report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics. 1992 May 1, 1992;89(5):942-9.
41. Landier W, Bhatia S, Eshelman DA, Forte KJ, Sweeney T, Hester AL, et al. Development of Risk-Based Guidelines for Pediatric Cancer Survivors: The Children's Oncology Group Long-Term Follow-Up Guidelines From the Children's Oncology Group Late Effects Committee and Nursing Discipline. Journal of Clinical Oncology. 2004 December 15, 2004;22(24):4979-90.
42. Lee BH, Goodenday LS, Muswick GJ, Yasnoff WA, Leighton RF, Skeel RT. Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol. 1987 Jan;9(1):184-8.
43. Meinardi MT, van der Graff WT, van Veldhisen DJ, Gietema JA, de Vries EG, Sleijfer DT. Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev. 1999 Aug;25(4);237-47.
44. Ali MK, Buzdar AU, Ewer MS, Cheng RS, Haynie TP. Noninvasive cardiac evaluation of patients receiving adriamycin-containing adjuvant chemotherapy (FAC) for stage II or III breast cancer. J Surg Oncol. 1983 Jul;23(3):212-6.
45. Wiginton CD, Kelly B, Oto A, Jesse M, Aristimuno P, Ernst R, et al. Gadolinium-Based Contrast Exposure, Nephrogenic Systemic Fibrosis, and Gadolinium Detection in Tissue. Am J Roentgenol. 2008 April 1, 2008; 190(4):1060-8.